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Diagnosis of fungal allergies in asthma remains problematic in low-and middle-income coun-
tries due to non-availability of point-of-care testing. In this study, we aimed to evaluate the
performance of an Aspergillus immunochromatographic technology (ICT) IgG/M lateral flow
device (LFD) for the serological diagnosis of allergic bronchopulmonary aspergillosis
(ABPA) and severe asthma with fungal sensitisation (SAFS) among Ugandan adult
asthmatics.
Methods
374 adult (aged�18years) asthmatics in the African Severe Asthma Program study, Ugan-
dan site constituted the study population. ABPA and SAFS were diagnosed according to
standard criteria. Asthmatics who did not meet the above criteria constituted a control
group. The LFD tests were performed and read according to manufacturer’s instructions.
Results
ABPA was found in 12/374 (3.2%) and SAFS in 60/374 (16%) participants. The sensitivity,
specificity, positive predictive value (PPV) and negative predictive value (NPV) for the
Aspergillus ICT for the diagnosis of ABPA were 0.0%, 96.4%, 0.0% and 96.7% respectively,
and for SAFS 6.7%, 97.1%, 30.8% and 84.5% respectively. False positive and negative
rates were 3.5% and 3.2% for ABPA and 2.4% and 14.9% for SAFS, respectively. Patients
PLOS ONE







Citation: Kwizera R, Bongomin F, Olum R,
Worodria W, Bwanga F, Meya DB, et al. (2021)
Evaluation of an Aspergillus IgG/IgM lateral flow
assay for serodiagnosis of fungal asthma in
Uganda. PLoS ONE 16(5): e0252553. https://doi.
org/10.1371/journal.pone.0252553
Editor: Aleksandra Barac, Clinic for Infectious and
tropical diseases, Clinical centre of Serbia, SERBIA
Received: February 22, 2021
Accepted: April 28, 2021
Published: May 28, 2021
Copyright: © 2021 Kwizera et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All data are available
in the paper and its Supporting Information files
without restriction.
Funding: RK was supported through the DELTAS
Africa Initiative grant # DEL-15-011 to THRiVE-2.
The DELTAS Africa Initiative is an independent
funding scheme of the African Academy of
Sciences (AAS)’s Alliance for Accelerating
Excellence in Science in Africa (AESA) and
supported by the New Partnership for Africa’s
Development Planning and Coordinating Agency
with a positive LFD significantly had higher median Aspergillus fumigatus-specific IgE levels
compared to those with negative LFD (median: 0.06 kUA/l VS 0.03 kUA/L, P = 0.011).
Conclusion
The Aspergillus ICT IgG/M LFD had a poor diagnostic performance for the diagnosis of both
ABPA and SAFS. Its greatest value may be in distinguishing chronic and allergic aspergillo-
sis in Africa.
Introduction
Airway exposures to fungal elements among patients with asthma elicits immune responses
and bronchopulmonary inflammation, typically presenting as severe asthma with fungal sensi-
tization (SAFS) or allergic bronchopulmonary aspergillosis (ABPA) [1]. Aspergillus fumigatus
is the usual culprit in fungal sensitization complicating 15–50% of cases of bronchial asthma,
and associated with poor disease control [2]. On a global scale, ABPA alone is diagnosed in 1
to 4% of adult asthma patients [3–7]. Asthma prevalence is estimated at 11% in Uganda [8].
Fungal asthma is a significant problem among Ugandans with asthma [9]. Our recent work
has shown that approximately over 4 million adult asthmatics in Africa have fungal sensitiza-
tion, with an estimated 437,000 presenting with ABPA and 577,000 SAFS [10].
Diagnosis of Aspergillus sensitization requires demonstration of evidence of allergic sensiti-
sation to Aspergillus either by skin prick testing (SPT) or Aspergillus-specific IgE immunoas-
says [5, 11, 12]. Other tests such as Aspergillus-specific IgG, total serum IgE and eosinophil
count can be added to get a definite diagnosis of ABPA as proposed by Agarwal and colleagues
[13]. High resolution chest CT scan may be added to distinguish between “serological ABPA”
and “ABPA with bronchiectasis” [14]. SAFS is diagnosed in a patient with severe asthma with
evidence of fungal sensitization after ABPA has been excluded [15]. However, most of these
approaches are hardly performed routinely in the resource-limited settings since they are
costly and need referral laboratory facilities.
Recently, Aspergillus lateral flow devices (LFD) have been developed as new point of care
diagnostic tests for the qualitative detection of Aspergillus antigens or antibodies in human
serum and bronchoalveolar lavage (BAL) fluid [16, 17]. They were recently added to the
World Health Organization (WHO) essential diagnostics list (https://www.gaffi.org/3rd-
essential-diagnostics-list-launch/). The Aspergillus antigen test is recommended for the diag-
nosis of invasive aspergillosis (IA) [16, 18] while the Aspergillus antibody test is recommended
for the diagnosis of chronic pulmonary aspergillosis (CPA) [19]. However, it is not yet
approved for diagnosis of ABPA or SAFS.
A novel Aspergillus immunochromatography technology (ICT) IgG-IgM (LDBio Diagnos-
tics, Lyon, France) test has been developed, and allows the simultaneous detection of both IgG
and IgM class anti-Aspergillus antibodies in blood. It is based on the principle of the sandwich.
It has been tested in France and the United Kingdom and might in fact be more useful in
resource-limited setting because of its simplicity and cost [20, 21]. It has a sensitivity and speci-
ficity of 91.6% and 98.0% respectively for the serological diagnosis of chronic pulmonary
aspergillosis (CPA) [20]. A recent study showed that the LDBio Aspergillus ICT has an excel-
lent diagnostic performance for the serological diagnosis of ABPA [22]; however, the utility of
this kit for the diagnosis of SAFS and ABPA in Africa has not been studied before. We there-
fore aimed to evaluate the diagnostic performance of the LD Bio Aspergillus ICT IgG-IgM
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lateral flow assay for the serological diagnosis of ABPA and SAFS among Ugandan adult
asthmatics.
Materials and methods
Study design and population
This was a cross-sectional study evaluating the diagnostic performance of the LDBio Aspergil-
lus ICT IgG-IgM lateral flow assay for the serological diagnosis of ABPA and SAFS among
Ugandan adult asthmatics. This study was nested within the African Severe Asthma Program
(ASAP) clinical study (ClinicalTrials.gov Identifier: NCT03065920) [23–25] at the Makerere
University Lung Institute. ASAP is a clinical study with the primary objective being to identify
and characterize severe asthma in Uganda, Kenya, and Ethiopia.
All participants in the current study were adults (�18years) enrolled in ASAP at the Ugan-
dan site having a “current/previous doctor diagnosis of asthma or clinical/treated asthma or
wheezing/whistling breath in the last 12 months”. Patients with an alternative lung disease
likely to confound assessment of asthma, those unable to perform study tests and procedures
and pregnant women were excluded. Each patient was followed up for 12 months.
Case definition for ABPA and SAFS
For this study, we used the case definition for SAFS and ABPA as proposed by ABPA compli-
cating asthma International Society for Human & Animal Mycology (ISHAM) working group
[13]. Table 1 summarises this case definition (Table 1). Any patients who did not fit this case
definition were taken as controls.
Study assays and cut-offs
Samples used for this study were stored baseline serum samples from the ASAP study popula-
tion at the Ugandan site (stored at -80˚C). Samples testing was performed via ImmunoCAP1
(ThermoFisher, previously Phadia) for levels of Aspergillus fumigatus -specific IgG (Asp IgG),
Aspergillus fumigatus-specific IgE (Asp IgE) and total serum IgE (TIgE) antibodies. We used
cut-offs of 40 mg/l for the Asp IgG and 0.35 kUA/l for Asp IgE as recommended by manufac-
turer. We used a cut-off of 113.9 kU/L for total IgE as recommended by manufacturer and a
Table 1. Case definition for SAFS and ABPA.
Aspergillus sensitisation Positive AF SPT or AF IgE
ABPA Positive TIgE >1000 IU/mL and
Positive AF SPT or Asp IgE and
AEC>500 cells/μL
SAFS Severe asthma and
Fungal sensitisation (Positive Asp SPT or Asp IgE) and
Positive TIgE <1000
ABPM Severe asthma and
Negative Asp IgE and Asp SPT and
Positive TIgE <1000
Positive MM SPT
Data presented are Case definitions for fungal asthma. ABPA = Allergic bronchopulmonary aspergillosis,
SAFS = Severe asthma with fungal sensitization, ABPM = Allergic bronchopulmonary mycosis, AF = Aspergilllus
fumigatus, SPT = skin prick test, Asp = Aspergillus, IgG = Immunoglobulin G, IgE = Immunoglobulin E,
TIgE = total Immunoglobulin E, AEC = absolute eosinophil count, MM = Mold mix.
https://doi.org/10.1371/journal.pone.0252553.t001
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cut-off of 1000 kU/L as a screen for ABPA [26]. A cut-off of 500 cells/ul for eosinophil was
used for ABPA [13].
Skin prick testing (SPT) (Immunospec (Pty) Ltd, Johannesburg, Gauteng, South Africa)
was performed at baseline for all patients, and the tests were performed and interpreted
according to international guidelines [27]. We used a panel of 12 allergens that included A.
fumigatus. Normal saline served as a negative control while histamine was the positive control,
with a mean wheal diameter of at least 3 mm being positive, read after 15 minutes of allergen
application.
Procedure for Aspergillus ICT IgG-IgM test
The Aspergillus ICT IgG-IgM is a rapid lateral flow test and was performed according to manu-
facturer’s instructions. In brief, 15μL of patient’s sample were added to the LFD followed by
four drops of sample diluent. This was left at room temperature and read after 20 minutes.
Two trained laboratory technologists visually read the test results.
Data analysis
Data were analysed using STATA version 14 (STATA, College Station, Texas). Descriptive sta-
tistics were used to summarize baseline characteristics including lung function of participants;
categorical variables as frequencies (percentages) and numerical variables as median (inter-
quartile range). Our primary data analysis aimed at establishing the diagnostic performance of
the LD Bio Aspergillus ICT IgG-IgM lateral flow assay for the diagnosis of ABPA and SAFS
among Ugandan adult asthmatics at a 95% confidence interval. We compared the Aspergillus
lateral flow assay to confirmed ABPA and SAFS so as to calculate the sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV) and level of agreement,
and receiver-operator characteristic (ROC) area under the curve (AUC) at a 95%CI. Mann-
Whitney U test was performed to compare the levels of Asp IgG, Asp IgE and TIgE in patients
with a positive and negative Asp LFD results.
Ethical statement
Participants provided written informed consent to participate in the ASAP study (MHREC
875). Ethics approval for this sub-study was received from the school of biomedical sciences
research and ethics committee (SBS 598), the Uganda National Council for Science and Tech-
nology (HS 2532) and the Uganda National Drug Authority (9464).
Results
Study population characteristics
Between May 2017 and June 2018, we enrolled 374 asthma patients in this study. Of 374
asthma patients included in the study, 286 (76.5%) were female and the median age for all par-
ticipants was 34 years (IQR 25–45; n = 369) (Table 2 and S1 Table). Of the 374 participants,
143 (38.2%) had a positive SPT against A. fumigatus, 16 (4.3%) had elevated A. fumigatus-
specific IgG levels, 27 (7.2%) had elevated A. fumigatus-specific IgE levels, 12 (3.2%) had
proven ABPA while 60 (16.0%) had proven SAFS. Of the 302/374 controls without ABPA or
SAFS, 85 had asthma with Aspergillus sensitization only, 11 had asthma with allergic broncho-
pulmonary mycosis (ABPM), while 206 had asthma without any form of fungal sensitization.
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Comparison of Aspergillus lateral flow assay against ImmunoCap
Aspergillus IgG, IgE and total IgE
Patients with a positive LFD significantly had higher median Asp IgE levels compared to those
with negative LFD (median: 0.06 kUA/l VS 0.03 kUA/L, P = 0.011). The differences in Asp
IgG and total IgE were not statistically significant (Fig 1).
Table 2. Selected baseline characteristics of the study population.
Overall (N = 374) Intermittent & mild asthma (N = 88) Moderate persistent & severe persistent
asthma (N = 286)
Characteristic N n (%) or median (IQR) N n (%) or median (IQR) N n (%) or median (IQR) P-value
Current age in years 369 34 (25–45) 88 29 (23–41) 281 35 (26–46) 0.013
Male Gender 374 88 (23.5) 88 20 (22.7) 286 68 (23.8) 0.839
Overall BMI 374 24.8 (21.6–29.5) 88 23.7 (20.9–28.9) 286 25.7 (21.6–29.7) 0.104
Mean ACQ 372
Well controlled 94 (25.3) 88 46 (52.3) 284 48 (16.8) 0.000
Not well controlled 278 (74.7) 42 (47.7) 236 (82.5)
Pre-measurements 88 286
FVC 374 2.9 (2.2–3.4) 3.3 (2.9–3.6) 2.7 (2.1–3.2) 0.000
FVC% 374 100 (83–112) 110 (103–120) 95.5 (78–109) 0.000
FEV1 374 2.1 (1.6–2.7) 2.6 (2.3–3.0) 1.97 (1.4–2.5) 0.000
FEV1% 374 88 (65–105) 103 (91.5–115.5) 79 (60–100) 0.000
FEV1/FVC ratio 374 0.76 (0.66–0.84) 0.82 (0.74–0.88) 0.73 (0.63–0.83) 0.000
Post-measurement 9 117
FVC 126 2.6 (2.2–3.4) 3.1 (2.8–3.6) 2.62 (2.2–3.4) 0.050
FVC % 126 99.5 (80–112) 117 (111–120) 97 (80–111) 0.002
FEV1 126 1.8 (1.3–2.3) 2.3 (2.1–2.5) 1.73 (1.29–2.2) 0.010
FEV1% 126 73.5 (56–89) 98 (92–103) 71 (56–87) 0.000
FEV1/FVC ratio 126 0.65 (0.56–0.71) 0.74 (0.7–0.76) 0.64 (0.56–0.71) 0.006
Eosinophil count 374 210 (110–390) 200 (110–410) 215 (100–390) 0.984
Patient uses ICS 370 34 (9.2) 87 3 (3.4) 283 31 (11) 0.034
Patient uses inhaler medication 370 108 (29.2) 87 13 (14.9) 283 95 (33.6) 0.001
Data presented are percentages (%), medians and interquartile ranges (IQR). BMI = body mass index, FVC = Forced vital capacity, FEV = Forced Expiratory Volume,
ACQ = Asthma Control Questionnaire, ICS = Inhaled corticosteroids.
https://doi.org/10.1371/journal.pone.0252553.t002
Fig 1. Distribution of levels of Asp IgG (A), Asp IgE (B) and Total IgE (C) in patients with a positive or negative LFD.
μ- median.
https://doi.org/10.1371/journal.pone.0252553.g001
PLOS ONE Aspergillus antibody lateral flow assay and fungal asthma
PLOS ONE | https://doi.org/10.1371/journal.pone.0252553 May 28, 2021 5 / 10
Performance of the Aspergillus lateral flow assay against ABPA
Using confirmed ABPA as the reference standard, the LDBio Aspergillus ICT IgG-IgM ICT
had a sensitivity of 0.0% (0/12), specificity of 96.4% (349/362), PPV of 0.0% (0/13) and a NPV
of 96.7% (349/361). We registered 13 (3.5%) false positives and 12 (3.2%) false negatives. There
was a 93.3% agreement between the two tests (ABPA vs LFD). However, Cohen’s Kappa analy-
sis [28] showed no level of agreement between the two tests (κ = -0.035, p = 0.748). The area
under the ROC curve for sensitivity and specificity showed poor performance (C-statistic =
0.48, 95% CI: 0.47 to 0.49) for the LDBio Aspergillus ICT IgG-IgM lateral flow assay when
compared to confirmed ABPA (Table 3). None of the patients with ABPA and 16 of the non-
ABPA patients had an elevated Aspergillus-specific IgG levels. Similarly, 24 of the non-ABPA
patients had an elevated Aspergillus-specific IgE levels.
Performance of the Aspergillus lateral flow assay against SAFS
Using confirmed SAFS as the reference standard, the LD Bio Aspergillus ICT IgG-IgM lateral
flow assay had a sensitivity of 6.7%% (4/60), specificity of 97.1% (305/314), PPV of 30.8% (4/
13) and a NPV of 84.5% (305/361). Nine (2.4%) false positive and 56 (14.9%) false negatives
tests were observed. There was an 82.6% agreement between the two tests. However, Cohen’s
Kappa [28] analysis showed no level of agreement between the two tests (κ = 0.056, p = 0.07).
The area under the ROC curve for sensitivity and specificity showed poor performance
(C-statistic = 0.52, 95% CI: 0.49 to 0.55) (Table 3). Two of the patients with SAFS and 14 of
the non-SAFS patients had an elevated Aspergillus-specific IgG levels. Similarly, 22 of the non-
SAFS patients had an elevated Aspergillus-specific IgE levels.
Discussion
Determination of serological evidence of Aspergillus sensitization through an ELISA-based
quantitative assay of total IgE and Aspergillus-specific IgE is an important component of the
Table 3. Summary of diagnostic performance of LD Bio Aspergillus ICT IgG-IgM lateral flow assay for the diag-
nosis of ABPA and SAFS.
Reference standard Confirmed ABPA Confirmed SAFS
n/N 12/374 60/374
True positives 0/12 (0.0%) 4/60 (6.7%)
False positives 13 (3.5%) 9 (2.4%)
False negatives 12 (3.2%) 56 (14.9%)
Sensitivity 95%CI 0.0% (0/12) (0.0% to 26.5%) 6.7%% (4/60) (1.9% to 16.2%)
Specificity 95%CI 96.4% (349/362) (93.9% to 98.1%) 97.1% (305/314) (94.6% to 98.7%)
PPV 95%CI 0.0% (0/13) (0.0% to 24.7%) 30.8% (4/13) (12.4% to 58.3%)
NPV 95%CI 96.7% (349/361) (96.6% to 96.7%) 84.5% (305/361) (83.5% to 85.4%)
% Agreement 95%CI 93.3% (90.3% to 95.6%) 82.6% (78.4% to 86.3%)
Kappa statistic P-value -0.035 (P<0.748) 0.056 (P<0.070)
C-Statistic 95%CI 0.48 (0.47 to 0.49) 0.52 (0.49 to 0.55)
Overall Diagnostic performance Poor Poor
Data presented are the numbers, percentages, numerator/denominator, and 95% confidence interval. N = number of
observations, ABPA = Allergic bronchopulmonary aspergillosis, SAFS = Severe Asthma with fungal sensitisation,
SPT = skin prick test, PPV = Positive predictive value, NPV = negative predictive value, C- statistic = receiver-
operator characteristic (ROC) area under the curve (AUC) for sensitivity and specificity. % agreement (Accuracy) =
overall probability that a patient is correctly classified.
https://doi.org/10.1371/journal.pone.0252553.t003
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diagnostic criteria for both ABPA and SAFS [29]. However, these tests are often expensive, not
available in most low- and middle-income countries (LMICs), labor intensive, and do require
uninterrupted supply of electricity in an established infrastructural setting such as a reference
laboratory [30]. These attributes limit their use in LMICs settings where they are most needed
[31]. Therefore, there is a need to leverage existing point of care platforms such as the LDBio
Aspergillus ICT to allow cheap and rapid serological screening for ABPA and other allergic
pulmonary fungal diseases.
Here, we report our findings from the evaluation of a novel Aspergillus-specific IgG/IgM LFD
for the serological diagnosis of ABPA and SAFS compared with a standard diagnostic criterion.
Our study findings suggest that the LDBio Aspergillus-specific IgG/IgM has a poor sensitivity and
should not be used alone for the diagnosis or screening for either ABPA or SAFS. None of the
participants with ABPA and less than 7% of participants with SAFS had a positive LFD test. Yet,
we previously demonstrated a 32% prevalence of Aspergillus sensitisation in the same Ugandan
population [32]. However, in both patients with ABPA and SAFS, the LFD had excellent specific-
ity (>96%) and very good NPV (>84%). This suggests that a negative LFD may be used as a rule
out test for fungal allergies in patients with asthma. However, more studies are needed to evaluate
its utility in this population. Interestingly, a recent evaluation of the same assay in Caucasian
patients with ABPA showed a much higher sensitivity of 90.6%, and a specificity of 87.2% [22].
The performance of LDBio Aspergillus-specific IgG/IgM LFD has been studied for the diag-
nosis of IPA, ABPA and chronic pulmonary aspergillosis (CPA). In a multicenter European
study among a diverse group of patients with pulmonary aspergillosis, the reported sensitivity
and specificity was 88.9% and 96.3%, respectively [21]. Similar, among a cohort of 154 patients
with CPA at the National Aspergillosis Centre in Manchester, UK, the reported sensitivity and
specificity of the kit was 91.6% and 98.0%, respectively [33]. In Indonesian patients with
proven CPA, LDBio LFD had a sensitivity of 80% and a specificity of 70% [34]. From these
studies, LDBio kit has been demonstrated to meet the ASSURED (“affordable, sensitive, spe-
cific, user-friendly, rapid and robust, equipment-free, and deliverable to end users”) criteria
outlined by the WHO [35].
Our study is not without limitations. The sample size could have been suboptimal. We did
not include radiology which would help to rule out any cases of CPA complicating fungal
asthma in this population. We used a single diagnostic criterion, yet the prevalence of ABPA
varies with the diagnostic criteria or case definition used. A recent study revealed that new
diagnostic criteria, principally a lower IgE level, compared with existing criteria, showed better
sensitivity and specificity for diagnosing ABPA [36]. We likely over diagnosed some patients
as ABPA since we only had available some of the key data required as criteria. Similarly, the
high prevalence of SAFS could be related to the very high prevalence of severe asthma (76.5%)
in this cohort, and thus may not truly reflect the prevalence of the disease among the general
population of individuals with asthma in Uganda. However, the strength of our study in the
use of data from patients with proven ABPA/SAFS using standard diagnostic criteria. Also,
patients and controls were derived from a homogenous population–that is, we used diseased
controls consisting of patients with asthma without ABPA or SAFS thus accurately represent-
ing the population and setting in which the test is most likely to be used.
Conclusion
In conclusion, the LDBio Aspergillus ICT IgG-IgM lateral flow assay had a poor diagnostic
performance for the diagnosis of both ABPA and SAFS in Uganda. However, with its high
specificity, it could be used to rule out these disorders. It may be particularly useful in distin-
guishing chronic and allergic aspergillosis in Africa.
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